Immunome Insider Trades

+2.04 (+8.84 %)
(As of 09/23/2021 01:10 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,092 shs
Average Volume293,238 shs
Market Capitalization$296.65 million
P/E RatioN/A
Dividend YieldN/A

Immunome (NASDAQ:IMNM) Insider Buying and Selling Activity

19.20% of Immunome's shares are owned by company executives, directors and other insiders. Over the past twelve months, Immunome insiders have purchased shares 6 time(s), totalling $2,301,461.07. Insiders that have bought shares include Michael Rapp, Michael Lefenfeld, and Purnanand D. Sarma.

Insider Buying and Selling by Quarter

Immunome (NASDAQ IMNM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2021Michael RappDirectorBuy25,962$19.96$518,201.52799,866  
9/9/2021Michael RappDirectorBuy30,450$18.19$553,885.50799,866  
5/26/2021Michael LefenfeldDirectorBuy1,335$19.03$25,405.0522,822  
5/25/2021Purnanand D. SarmaCEOBuy10,500$18.41$193,305.0010,500  
5/24/2021Michael LefenfeldDirectorBuy600$17.80$10,680.0046,726  
10/6/2020Michael RappDirectorBuy83,332$12.00$999,984.00555,554  
(Data available from 1/1/2013 forward)
speech bubbles
speech bubbles

Immunome (NASDAQ:IMNM) Insider Trade Frequently Asked Questions

Who is on Immunome's Insider Roster?

The list of insiders at Immunome includes Michael Lefenfeld, Michael Rapp, and Purnanand D. Sarma.Learn more on IMNM's insiders

What percentage of Immunome stock is owned by insiders?

19.20% of Immunome stock is owned by insiders. Learn more on IMNM's insider holdings

Which Immunome insiders have been buying company stock?

The following insiders have purchased Immunome stock in the last 24 months: Michael Lefenfeld ($36,085.05), Michael Rapp ($2,072,071.02), and Purnanand D. Sarma ($193,305.00).

How much insider buying is happening at Immunome?

Insiders have purchased a total of 152,179 Immunome shares in the last 24 months for a total of $2,301,461.07 bought.

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.